Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells (ProTrans19+)
Treatment of Respiratory Complications Associated With COVID-19 Infection Using Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®): a Randomized Phase II Controlled Clinical Trial
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Terminated
DSMB advised discontinuing the study prematurely because recruitment goals were not achieved.
Other terminated trials from McGill University Health Centre/Research Institute of the McGill University Health Centre
A PHASE2 clinical study on Covid19, this trial is terminated or withdrawn. The trial is conducted by McGill University Health Centre/Research Institute of the McGill University Health Centre and has accumulated 7 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
7 versions recorded-
Oct 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Oct 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Apr 2023 — Jul 2023 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Sep 2021 — Apr 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- McGill University Health Centre/Research Institute of the McGill University Health Centre
For direct contact, visit the study record on ClinicalTrials.gov .